Developing Antitussive Alternatives To DXM Would Offset Commercial Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of new OTC antitussives is an immature area of study and a major unmet medical need that could help protect manufacturers from lost sales if dextromethorphan is no longer available OTC in the future.
You may also be interested in...
Adding Zarbee's, J&J Gains Natural Market Footprint, Claims Credibility
Zarbee's Naturals vitamin, mineral and dietary supplement products were launched in 2008 by a physician interested in offering non-drug alternative remedies for children and adults for indications such as cough and cold, sore throat, immune support, sleep and digestive health. J&J on the other hand, has been challenged in class action litigation about natural claims it's used on some of its Aveeno and Neutgrogena skin care product labels.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.